SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2020 / Cilt: 2 - Sayı: 1

Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience

Emel ISİKTAS SAYİLAR
Alparslan ERSOY
Sedat ÇELİKÇİ
Yavuz AYAR
Fahir ÖZKALEMKAŞ
Vildan OZKOCAMAN
Rıdvan ALİ
Pages
11–18
Publication Date
2020-01-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Eight kidney transplant recipients treated with G-CSF for drug-induced neutropenia (neutrophil count

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Granulocyte colony-stimulating factor (G-CSF) therapy is commonly used in kidney and liver transplant recipients with severe neutropenia.
📊
Key Findings & Data:However, rapid and high increases in neutrophil counts of some patients may occur during treatment.
💡
Conclusion & Impact:Eight kidney transplant recipients treated with G-CSF for drug-induced neutropenia (neutrophil count
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Filgrastim · granulocyte colony-stimulating factor · kidney transplantation

Abstract

Introduction. Granulocyte colony-stimulating factor (G-CSF) therapy is commonly used in kidney and liver transplant recipients with severe neutropenia. However, rapid and high increases in neutrophil counts of some patients may occur during treatment. This retrospective study aimed to determine the efficacy and safety of G-CSF treatment in neutropenic kidney transplant recipients. Methods. Eight kidney transplant recipients treated with G-CSF for drug-induced neutropenia (neutrophil count

🔖

Cite This Article

SAYİLAR, E. I., ERSOY, A., ÇELİKÇİ, S., AYAR, Y., ÖZKALEMKAŞ, F., OZKOCAMAN, V., ALİ, R. (2020). Granulocyte colony-stimulating factor usage in drug-induced neutropenia after kidney transplantation: a single-center experience. Turkish Journal of Internal Medicine, Cilt: 2 - Sayı: 1, 11–18. https://ajindex.com/articles/809131

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Zafrani L, Truffaut L, Kreis H, Etienne D, Rafat C, Lechaton S, Anglicheau D, Zuber J, Ciroldi M, Thervet E, Snanoudj R, Mamzer MF, Martinez F, Timsit MO, Bergougnoux L, Legendre C. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant. 2009 Aug;9(8):1816-25. doi: 10.1111/j.1600-6143.2009.02699.x. Hurst FP, Belur P, Nee R, Agodoa LY, Patel P, Abbott KC, Jindal RM. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States Renal Data System. Transplantation. 2011 Jul 15;92(1):36-40. doi: 10.1097/TP.0b013e31821c1e70. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, Dolan S, Kano JM, Mahon M, Schnitzler MA, Woodward R, Irish W, Ramachamdra V, Singer GG. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc. 1999 May;31(3B Suppl):16S-18S. Moreso F, Serón D, Morales JM, Cruzado JM, Gil-Vernet S, Pérez JL, Fulladosa X, Andrés A, Grinyó JM. Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant. 1998 Jun;12(3):198-205.
  2. Hong JC, Kahan BD. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000 May 27;69(10):2085-90.
  3. Taber DJ, Ashcraft E, Baillie GM, Berkman S, Rogers J, Baliga PK, Rajagopalan PR, Lin A, Emovon O, Afzal F, Chavin KD. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis. 2004 Sep;6(3):101-9.
  4. Keles M, Yildirim R, Uyanik A, Turkmen M, Bilen Y, Aydinli B, Cetinkaya R, Polat KY. Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report. Exp Clin Transplant. 2010 Jun;8(2):181-3.
  5. Kutsogiannis DJ, Crowther MA, Lazarovits AI. Granulocyte macrophage colony-stimulating factor for the therapy of cytomegalovirus and ganciclovir-induced leukopenia in a renal transplant recipient. Transplantation. 1992 Apr;53(4):930-2.
  6. Bradley PP, Warden GD, Maxwell JG, Rothstein G. Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1980 Oct;93(4):560-2.
  7. Derici U, Ayerdem F, Ari